Global R&D Center
- 2021-10-28
Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?
Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.
- 2021-10-07
Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai
On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association,
- 2021-09-28
2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer
In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.
- 2021-09-28
2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosimilar HLX04 for Treatment of Metastatic Colorectal Cancer
In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
-
Fosun Pharma started its innovation and R&D in 2009 and made great progress in R&D efficiency, system construction and international influence since 2017.
By the end of 2024, the company had more than 80 projects for drugs under development (calculated by indications), including innovator drugs, biosimilars. In 2024, the company applied for 220 patents in the pharmaceutical manufacturing segment, including 3 US patents and 18 PCT applications, with 66 patents granted.
According to 2024 Annual Report
*Unit: RMB billion yuan-
55.54 million
R&D investment in 2024
-
3,047
R&D personnel
-
1,600+
Personnel with master's degree or above
-
-
In China
-
- 20
- Concurrent clinical trials
-
- 7
- IND applications
-
- 3
- NDA applications
In The United States And Australia
-
- 3
- Clinical trials
-
- 1
- IND application
-
- 2 项
- IND approvals
-
- Double-antibody
-
- Stem cell therapy
-
- mRNA therapy
-
- Gene editing
-
- Tumor/immunology
-
- Central Nervous System
-
- Metabolic/chronic diseases
-
- Infectious/rare diseases